Inventor · disambiguated record
Christopher W. Lange
Also filed as: LANGE CHRISTOPHER · LANGE CHRISTOPHER W
47 granted patents·1 pending application·209 citations·filing 2008–2025
98Inventor score
Top patents by PatentIndex Score
48 records- 0198US11426364B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2020·Granted Aug 30, 2022·10 cites·6 claims
- 0297US11485708B2Compounds for treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Nov 1, 2022·9 cites·21 claims
- 0397US11266643B2Triaryl compounds for treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Mar 8, 2022·13 cites·32 claims
- 0497US11135210B2Indane-amines as PD-L1 antagonistsCHEMOCENTRYX INC·Filed 2020·Granted Oct 5, 2021·10 cites·23 claims
- 0597US10639284B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2017·Granted May 5, 2020·17 cites·30 claims
- 0696US11713307B2Heteroaryl-biphenyl amides for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Aug 1, 2023·8 cites·28 claims
- 0796US11478460B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·34 claims
- 0896US10919852B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2018·Granted Feb 16, 2021·15 cites·25 claims
- 0996US10568874B2Indane-amines as PD-L1 antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Feb 25, 2020·13 cites·26 claims
- 1096US10562896B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Feb 18, 2020·11 cites·38 claims
- 1195US11708326B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2020·Granted Jul 25, 2023·4 cites·25 claims
- 1294US11142521B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Oct 12, 2021·4 cites·6 claims
- 1394US10683294B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Jun 16, 2020·8 cites·31 claims
- 1493US11479553B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·24 claims
- 1593US11384079B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2019·Granted Jul 12, 2022·5 cites·18 claims
- 1693US10828285B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Nov 10, 2020·5 cites·27 claims
- 1792US11485737B2Diaryl substituted 5,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Nov 1, 2022·2 cites·29 claims
- 1892US9169261B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2013·Granted Oct 27, 2015·13 cites·26 claims
- 1991US11059825B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Jul 13, 2021·2 cites·11 claims
- 2090US10759807B2Diaryl substituted 5,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Sep 1, 2020·7 cites·38 claims
- 2190US9758512B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2016·Granted Sep 12, 2017·6 cites·24 claims
- 2288US8835419B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2012·Granted Sep 16, 2014·9 cites·30 claims
- 2387US9567323B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2014·Granted Feb 14, 2017·6 cites·9 claims
- 2487US7834185B2Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2008·Granted Nov 16, 2010·8 cites·43 claims
- 2586US10407417B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Sep 10, 2019·3 cites·12 claims
- 2686US9783544B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Oct 10, 2017·4 cites·26 claims
- 2781US9340509B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2014·Granted May 17, 2016·4 cites·17 claims
- 2880US12371433B2Heteroaryl-biphenyl amines for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2023·Granted Jul 29, 2025·0 cites·13 claims
- 2980US9795599B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2016·Granted Oct 24, 2017·2 cites·24 claims
- 3079US2025346598A1Heteroaryl-biphenyl amines for the treatment of pd-l1 diseasesCHEMOCENTRYX INC·Filed 2025·Application pending·0 cites
- 3178US11884654B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2021·Granted Jan 30, 2024·0 cites·15 claims
- 3278US11834452B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2021·Granted Dec 5, 2023·0 cites·14 claims
- 3378US10287292B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2017·Granted May 14, 2019·1 cites·7 claims
- 3478US10117865B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2017·Granted Nov 6, 2018·1 cites·6 claims
- 3575US12268675B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2022·Granted Apr 8, 2025·0 cites·16 claims
- 3675US11773091B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2022·Granted Oct 3, 2023·0 cites·20 claims
- 3774US12497383B2Heteroaryl-biphenyl amides for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2023·Granted Dec 16, 2025·0 cites·20 claims
- 3874US11793771B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2022·Granted Oct 24, 2023·0 cites·19 claims
- 3973US10786494B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2018·Granted Sep 29, 2020·0 cites·5 claims
- 4072US8293925B2Pyrrolidinone carboxamide derivativesCHARVAT TREVOR T·Filed 2010·Granted Oct 23, 2012·2 cites·15 claims
- 4171US11759458B2Indane-amines as PD-L1 antagonistsCHEMOCENTRYX INC·Filed 2021·Granted Sep 19, 2023·0 cites·20 claims
- 4271US8378121B2Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonistsTHERAVANCE INC·Filed 2010·Granted Feb 19, 2013·1 cites·39 claims
- 4368US11866429B2Heteroaryl-biphenyl amines for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Jan 9, 2024·0 cites·26 claims
- 4460US12448373B2Azetidinyl-acetamides as CXCR7 inhibitorsCHEMOCENTRYX INC·Filed 2022·Granted Oct 21, 2025·0 cites·30 claims
- 4560US12018016B2Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitorsCHEMOCENTRYX INC·Filed 2022·Granted Jun 25, 2024·0 cites·59 claims
- 4660US8802856B2Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonistsJI YUHUA·Filed 2013·Granted Aug 12, 2014·0 cites·37 claims
- 4753US8592453B2Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonistsJI YUHUA·Filed 2010·Granted Nov 26, 2013·0 cites·39 claims
- 4850US8716494B2Pyrrolidinone carboxamide derivativesCHEMOCENTRYX INC·Filed 2012·Granted May 6, 2014·0 cites·25 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →